A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
创建时间：
2020-08-15
